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Abstract 
Purpose: To determine the prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency 
among staff and students of a university community in Malaysia as well as to identify molecular 
genetics by determination of G6PD mutations. 
Methods: Cross-sectional and experimental studies were carried out on the staff and students of 
Advanced Medical and Dental Institute (AMDI) of Universiti Sains Malaysia (USM) from July 2009 to 
April 2010. Venous blood samples were collected from 87 individuals (45 males and 42 females), all of 
whom gave informed consent. Full blood count, reticulocyte count, screening test and quantitative 
determination of G6PD were performed. The deficient subjects were confirmed by standard PCR 
restriction enzyme. DNA samples from these subjects were analyzed for certain known G6PD 
mutations by digesting them with appropriate restriction enzymes.  
Results: Out of the 87 subjects (80 were Malay, 2 were Chinese, 1 was Indian and 4 were others). 
The total prevalence of G6PD deficiency among the subjects was 4.59 % (4/87), all of whom were 
Malay males. One of the deficient subjects had G6PD Viangchan, while the other three were G6PD 
Mahidol (487 G>A). 
Conclusion: The finding of this study demonstrate that the most common mutation among AMDI staff 
and students is Mahidol (487G>A), followed by mutation Viangchan (871G>A).  
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G6PD deficiency is the most common human 
enzyme defect, being present in more than 400 
million people globally. This condition occurs 
most frequently in certain parts of Africa, Asia, 
and the Mediterranean region. It affects about 
one-tenth of African-American males in the 
United States. The worldwide distribution of this 
disorder is remarkably similar to that of malaria 
[1]. G6PD enzyme protects RBCs from harmful 
by-products that are produced as a result of 
taking certain medications or when the body is 
fighting an infection. 
 
In people with G6PD deficiency, either the 
RBCs do not make enough G6PD or what is 
produced cannot properly function. Without 
enough G6PD to protect them, RBCs can be 
damaged or destroyed. Haemolytic anaemia 
occurs when the bone marrow cannot 
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compensate for this destruction by increasing 
its production of RBCs. G6PD is a 
housekeeping enzyme that plays an essential 
role in reducing nicotinamide adenine 
dinucleotide phosphate (NADP) to NADPH. In a 
reaction catalyzed by G6PD, electrons 
generated by the conversion of glucose-6-
phosphate (G6P) to 6-phosphogluconate (6PG) 
are transferred to NADP [2].  
 
The main problem in G6PD-deficient individuals 
occurs immediately after birth. Neonatal 
jaundice and chronic haemolytic anaemia are 
caused by this inherited disorder. Although 
most affected individuals are asymptomatic, the 
exposures to oxidative stressors such as 
certain drugs or infections are the cause of 
morbidity from G6PD deficiency [3]. G6PD 
deficiency is a genetic disorder that occurs 
most frequently in males. It is an X-linked 
genetic disorder. About 140 mutations have 
been described, in which most are single base 
changes, leading to amino acid substitutions. 
However, the majority of the mutations cause 
red cell enzyme deficiency due to the decrease 
of the enzyme stability. The most important 
clinical manifestation of G6PD deficiency is 
severe neonatal hyperbilirubinemia. A neonatal 
screening program using fluorescent spot test 
has been installed in all public hospitals since 
1980 [4]. 
 
In this study, our attention was focused on the 
determination of the prevalence of G6PD 
deficiency and the predominant mutation 
(Viangchan or Mahidol) among the staff and 
students of Advanced Medical and Dental 
Institute (AMDI) of Universiti Sains Malaysia 
(USM). Also it aimed to check out the 





Blood samples (5mL) were collected from the 
cubital vein of the forearm of 87 participants 
who had given informed consent.  
 
Blood samples were processed and subjected 
to full blood count (FBC) analysis using blood 
counter Sysmex KX-21 for screening of 
hemoglobin (Hb), white blood cells (WBC`s), 
red blood cells (RBC`s), platelets (PLT`s), 
hematocrite (HCT), mean cell volume (MCV), 
mean cell hemoglobin (MCH), mean cell 
hemoglobin concentration (MCHC) and cells 
morphology. Manual reticulocyte count 
(Retic`s) was carried out using new methylene 
blue stain for detection of non-nucleated 
immature red cell containing residual RNA. The 
G6PD deficiency screening was investigated 
using fluorescent spot test  and G6PD assay 
activity using Selectra-E (All Eights (M) SDN 
BHD) to detect and investigate the deficient 
samples.   
 
G6PD enzyme activity was calculated as 
haemoglobin (Hb) U/g by Eq 1. 
 
G6PD mU/g Hb = mU. RBC  per ml x 100/Hb 
(g/dl) ……………………. (1) 
 
 where 100 = factor to convert activity to 100 
ml, and Hb(g/dl) = haemoglobin concentration 
determined for each sample. 
 
This study was approved by the Ethics and 
Research Committee of AMDI, USM (USM / 
Human Ethics Approval /2009/ (21) (134)). The 
participants signed a consent form before blood 
sample collection and Helsinki Declaration 
guidelines were followed in this study (11). 
 
The G6PD deficient samples were analyzed by 
polymerase chain reaction (PCR) using 
Thermal Cycler (BioRad MyCycler, USA) and 
restriction enzyme digest to determine mutation 
variants.  
 
PCR was used to amplify specific regions of the 
extracted DNA. PCR was carried out on 4 
deficient samples and 1 normal subject as a 
control and it was performed on a volume of 25 
µl (including 12.5 µl of GoTaq green master 
mix). To determine G6PD Viangchan (871G>A) 
mutation, a mutagenic primer pair, 871F (5-
TGGCTTTCTCTCAGGTCTAG-3) and 871R (5-
GTCGTCCAGGTACCCTTTGGGG-3), were used.  
The primers were used to target exon 9 in 
PCR.  
 
PCR amplification was performed on the DNA 
thermal cycler as follows: 1 cycle at 95 oC for 5 
min, then 35 cycles at 95 oC for 1 min, 56 oC for 
1 min ,72 oC for 1 min, and final extension at 72 
oC for 10 min. Ten microlitres of PCR product 
was digested with 20 µl (10 U) of XbaI 
restriction enzyme for 2 h, and then resolved on 
3 % agarose gel containing ethidium bromide 
as previously described [7]. A mutagenic primer 
pair, 487F (5-GCGTCTGAATGATGCAGCT 
CTGAT-3) and 487R (5-CTCCACGATGATCG 
GTTCAAGC-3), were used for G6PD Mahido 
(487 G>A) mutation assay. The primers were 
used to target exon 6. The PCR reaction was 
the same as described in the previous test 
except the restriction enzyme used was HindIII. 
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The data obtained were analyzed using 
Statistical Package for Social Sciences (SPSS) 
version 17. Using Independent samples t-test, 
differences between data for normal and 
G6PD-deficient subjects were considered 




Out of a total of 87 subjects (45 males and 42 
females), 80 were Malay, 2 were Chinese, 1 
was Indian and 4 were other ethnic groups. The 
prevalence of G6PD-deficient individuals 
among the subjects was 4.6 %.  The ethnic 
group of all deficient subjects was Malay and 
they were all males. Out of the 87 subjects, 
there were four G6PD-deficient subjects, 
representing 4.6 % (4/87) of all samples and 
8.9 % (4/45) of male subjects.  
 
Table 1 shows the blood count parameters - 
WBC, RBC, Hb, PLT, and Ret - for the four 
G6PD-deficient subjects. All the blood count 
parameters in the four G6PD-deficient`s 
subjects were within normal ranges. 
 
G6PD activity results are listed in Table 2. The 
highest value among G6PD-deficient subjects 
was 3.38 U/g Hb while the lowest was 2.92 U/g 
Hb. Table 3 shows the p-values for the blood 
parameters and G6PD activity. The difference 
between the normal and G6PD-deficient subjects 
were not significant except for G6PD enzyme 
activity (p < 0.001). 
 
Table 1:  Blood count parameters of the four G6PD-deficient subjects 
 












1 8.8×103 4.95×106 14.3 204×103 0.7 
2 3.7×103 5.26×106 14.3 331×103 1.2 
3 5.6×103 5.36×106 15.8 209×103 1.0 
4 8.7×103 5.24×106 15.1 267×103 1.1 
 
Table 2:  G6PD activity of the subjects 
 
Subject type Number of 
subjects 
G6PD enzyme  activity U/g Hb 
(mean ± SD) 
All subjects 87 8.75 ± 1.82 
Normal subjects 83 9.02 ± 1.36 
G6PD-deficient subjects 4 3.19 ± 0.19 
       
Table 3:  Blood parameters and G6PD and their corresponding p-values* (values in parenthesis denote standard 
deviation) 
 
Parameter Normal subjects  G6PD-deficient subjects  P-value 
RBC/µl x 106 5.01 (0.57) 5.20 (0.18) 0.12 
HGB (g/dL) 13.65 (1.69) 14.88 (0.72) 0.15 
HCT (%) 42.29 (4.64) 38.05 (16.12) 0.63 
MCV (fL) 84.67 (5.92) 87.53 (2.82) 0.34 
MCH (pg) 27.36 (2.58) 28.60 (0.98) 0.34 
MCHC (g/dL) 32.25 (1.24) 32.68 (0.49) 0.50 
PLT x10³ 289.20 (60.30) 252.75 (59.49) 0.24 
G6PD activity (U/g Hb) 9.02 (1.36) 3.19 (0.19) < 0.001 
Ret (%) 1.24 (0.36) 1.00 (0.22) 0.12 
*Independent- samples t- test, p < 0.05 
 
First and second PCR product of exon 6 
 
One out of 4 deficient subjects showed G6PD 
Viangchan mutation at nt (871 G→A) while the 
rest of the three samples were investigated for 
further mutation abnormality at exon 6. The result 
of the first PCR product at exon 6 of the three 
subjects showed 3 identical bands (Figure 1).  
 
The second amplification process, PCR–
restriction enzyme and  digested PCR product at 
exon 6 using restriction enzyme HindIII illustrates 
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that all the three deficient subjects were carrying 




Figure 1:  First PCR products of exon 6; agarose gel 
electrophoresis (3 %) of first PCR products of exon 6. 
Note: Lane 1 = Ladder DNA (100bp), Lanes 2, 3 and 4 
= PCR products for the three subjects, Lane 5 = 





Figure 2: PCR products digest with HindIII restriction 
enzyme for G6PD Mahidol; agarose gel 
electrophoresis.  
Note: Lane 1 = Ladder DNA (100 bp) = Lane 2, 3, 4 
subjects’ samples show cut with restriction enzyme 
HindIII at 82pb band which corresponds to Mahidol 
mutation (487G→A), Lane 5 = positive normal control 
(104bp). 
 
First and second PCR product at exon 9 
 
The result of first PCR product at exon 9 of the 
four deficient subjects showed 4 bands, 
indicating a successful amplification process 
(Figure 3). The second amplification process,  
PCR restriction enzyme of the four deficient 
subjects, was digested using restriction enzyme 
XbaI. Figure 4 illustrates  the   mutation of  G6PD 




Figure 3: First PCR product at exon 9; agarose gel 
electrophoresis (3 %) shows first PCR product at exon 
9 of the 4 subjects. 
Note: Lane 1 = Ladder DNA (100bp), Lanes 2 – 5 = 
PCR product of the four subjects. The second 
amplification PCR process was carried out after the 




Figure 4: PCR products’ digest with XbaI restriction 
enzyme for G6PD Viangchan.  
Note: PCR was performed on genomic DNA for the 
four deficient subjects. All the G6PD-deficient subjects 
in this study had a normal full blood count and 
reticulocyte count, which indicates that they didn’t 




The findings of the present study are in 
agreement with those of previous studies [6,7]. In 
this study, the majorty of ethnic groups (male and 
female) were Malay. The results indicate a higher 
prevalence of G6PD among males than females. 
A similar observation was reported in Thailand by 
Nuchprayoon et al [8] who found that the 
deficiency in males and females was 11.1 and 
5.8 %. Furthermore, in previous studies on Malay 
and Chinese neonates with G6PD deficiency in 
Malaysia, it appeared that the majority of the 
male G6PD-deficient neonates exhibited severe 
enzyme deficiency [7,9]. G6PD deficiency was 
found to be more prevalent among Malay and 
Malaysian Chinese ethnic groups and less 
among Indians [4,10]. 
 
The mean G6PD activity of 3.19 found in the 
present study is below the normal range (6.97 to 
Lane 1           2              3              4          5             6 
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20.5 U/g Hb) indicated by the manufacturer of 
the test kit used (Randox Kits).  
 
Standard PCR and restriction enzyme analyses 
were carried out to determine the molecular 
genetic mutations of the deficient subjects. The 
extracted genomic DNA was amplified  by using 
reverse and forward primers designed to be 
targeted at exon 6 of the G6PD gene for Mahidol 
mutation and at exon 9 of the G6PD gene for 
Viangchan mutation. Therefore, exons 6 and 9 
can be deemed as point mutations and the 
mutations would be expected to be found in 
these sites. One G6PD Viangchan mutation and 
three G6PD Mahidol mutations were found in the 
four deficient samples, and all of these mutations 
are located in southeast Asia region. The G6PD 
Viangchan mutation found in this study are in 
subjects of Malay ethnic stock. This gives some 
support to the finding of Wang et al, [11] who 
observed this mutation in Orang Asli (aboriginal 
Malaysians) race.  This means that the mutation 
is common in Malaysia. In this study, 75 % of the 
deficient subjects (3 out of four subjects) had a 
Mahidol mutation and all of them were Malays. 
The  integration and closeness of people of these 
two countries may, amongst other factors, 
explain the presence of high levels of G6PD in 
Malaysia. Four of the G6PD-deficient subjects 
didn’t have haemolytic anaemia and only one of 
them discovered for the first time that he has 




This study demonstrated that, the prevalence of 
G6PD deficiency among the students and staff of 
Malaysian descent is relatively high. In addition, 
this study reveals only two mutations - 
Viangchan and Mahidol. It is recommended that 
early screening for G6PD deficiency should be 
carried out and a comprehensive investigation 
using large sample size and more than 4 
mutations should be undertaken to reflect the full 
picture of the prevalence of G6PD in Malaysia.  
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